Evidence map›Paper›PMID 39617532›Full record

ArticleESMO open2024

Corrigendum to "Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18": [ESMO Open 8 (2023) 101588].

M Kim, J L Lee, S J Shin, W K Bae, H J Lee, J H Byun, Y J Choi, J Youk, C Y Ock, S Kim and 3 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

M KimDepartment of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul; Cancer Research Institute, Seoul National University College of Medicine, Seoul.
J L LeeDepartment of Oncology and Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul.
S J ShinDivision of Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul.
W K BaeDepartment of Hemato-Oncology, Chonnam National University Medical School & Hwasun Hospital, Hwasun.
H J LeeDepartment of Internal Medicine, Chungnam National University College of Medicine, Daejeon.
J H ByunDepartment of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon.
Y J ChoiDepartment of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul.
J YoukDepartment of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul; Cancer Research Institute, Seoul National University College of Medicine, Seoul.
C Y OckLunit, Seoul, Republic of Korea.
S KimLunit, Seoul, Republic of Korea.
H SongLunit, Seoul, Republic of Korea.
K H ParkDepartment of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul.
B KeamDepartment of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul; Cancer Research Institute, Seoul National University College of Medicine, Seoul. Electronic address: bhumsuk@snu.ac.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39617532
PMCPMC11670659

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.